Examining New Treatment Strategies Aimed at Stroke Prevention in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

Jennifer Costello, PharmD, BCPS, BC-ADM; Mindy Houng, MD, FACP; and Steven J. Sheris, MD, FACC, FACP
Published Online: Monday, March 17, 2014
Follow Pharmacy_Times:
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Examining New Treatment Strategies Aimed at Stroke Prevention in Patients with Atrial Fibrillation: A Multidisciplinary Discussion

Jennifer Costello, PharmD, BCPS, BC-ADM
Ambulatory Clinical Pharmacist
Internal Medicine Faculty Pharmacist
Saint Barnabas Medical Center
Livingston, New Jersey
 
Mindy Houng, MD, FACP
Associate Program Director
Internal Medicine Residency Program
Department of Medicine
Saint Barnabas Medical Center
Livingston, New Jersey
Clinical Assistant Professor
Department of Medicine
Rutgers University, New Jersey
Medical School
Newark, New Jersey
 
Steven J. Sheris, MD, FACC, FACP
Chief of Cardiology
Overlook Medical Center
Gagnon Cardiovascular Institute
Summit, New Jersey
 
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose
 
Faculty
Jennifer Costello, PharmD, BCPS, BC-ADM
Mindy Houng, MD, FACP
Steven J. Sheris, MD, FACC, FACP

Pharmacy Times Office of Continuing Professional Education
Planning StaffDavid Heckard; Steve Lin, PharmD, RPh; Maryjo Dixon, RPh; and Donna Fausak
 
Pharmacy Times
Editorial StaffBea Riemschneider and Kirk McKay

An anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objective
At the conclusion of this educational activity, participants should be able to:
  • Discuss the prevalence, epidemiology, and risk of stroke in patients with atrial fibrillation (AF).
  • Explore the underrecognized risk of stroke and inadequate prophylaxis in patients with AF.
  • Examine current guidelines, with respect to risk stratification recommendations for appropriate anticoagulation, and impact on patient outcomes.
  • Review newly approved oral anticoagulants and identify their practice-focused differences from warfarin and their role in stroke prevention.
  • Explore the pharmacist’s role in educating patients on the risk of stroke in AF, monitoring anticoagulation therapy, and participating in disease management opportunities.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: March 12, 2014
Expiration date: March 12, 2016
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this activity.
 
Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-015-H01-P. The activity is available for CE credit through March 12, 2016.

Related Articles
Teva has launched a generic version of aspirin and extended-release dipyridamole (Aggrenox) capsules in the United States.
A practice-changing study suggests bridging anticoagulation does more harm than good in atrial fibrillation (AF) patients treated with warfarin.
Studies have reported that up to half of patients discontinue prescribed therapies soon after hospital discharge.
Here are new drugs for 2015 pharmacists can expect to handle.
Latest Issues
$auto_registration$